What Cue Biopharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 5 |
| Sells | 15 | 15 |
| Total trades | 19 | 33 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 166,522 | 729,132 |
| Disposed | 86,790 | 86,790 |
| Net activity | +79,732 | +642,342 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ray Sumita | Chief Legal Compliance Officer | Oct 12 | Open-market sale · S | −1,844 | $28.05 | −$51.7K | 116,701 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Oct 12 | Open-market sale · S | −1,144 | $28.05 | −$32.1K | 47,817 |
| Lin Shao-Lee | Chief Executive Officer | Oct 12 | Open-market sale · S | −1,087 | $28.05 | −$30.5K | 694,908 |
| Lin Shao-Lee | Chief Executive Officer | Oct 12 | Open-market sale · S | −10,000 | $27.50 | −$275K | 695,995 |
| Lin Shao-Lee | Chief Executive Officer | Aug 13 | Open-market sale · S | −10,460 | $29.48 | −$308K | 705,995 |
| Lin Shao-Lee | Chief Executive Officer | Aug 13 | Open-market sale · S | −2,375 | $28.11 | −$66.8K | 716,455 |
| Lin Shao-Lee | Chief Executive Officer | Aug 13 | Open-market sale · S | −5,423 | $27.19 | −$147K | 718,830 |
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 | Open-market sale · S | −4 | $31.13 | −$125 | 118,545 |
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 | Open-market sale · S | −6,442 | $30.35 | −$196K | 118,549 |
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 | Open-market sale · S | −2,383 | $29.37 | −$70K | 124,991 |
| Ray Sumita | Chief Legal Compliance Officer | Aug 13 | Exercise / conversion · M | +18,196 | — | — | 127,374 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Aug 13 | Open-market sale · S | −3 | $31.13 | −$93.4 | 48,961 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Aug 13 | Open-market sale · S | −4,106 | $30.35 | −$125K | 48,964 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Aug 13 | Open-market sale · S | −1,519 | $29.37 | −$44.6K | 53,070 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | Aug 13 | Exercise / conversion · M | +13,647 | — | — | 54,589 |
| Lin Shao-Lee | Chief Executive Officer | Aug 12 | Open-market sale · S | −5,775 | $27.75 | −$160K | 724,253 |
| Lin Shao-Lee | Chief Executive Officer | Aug 12 | Open-market sale · S | −34,225 | $26.99 | −$924K | 730,028 |
| Lin Shao-Lee | Chief Executive Officer | Aug 12 | Exercise / conversion · M | +109,179 | — | — | 764,253 |
| Ahlers James M | Chief Financial Officer | Jul 30 | Grant / award · A | +25,500 | — | — | 25,500 |
| Borie Dominique Christian | Chief Medical Officer | Jul 13 | Grant / award · A | +31,500 | — | — | 31,500 |
Loading...